跳至主要内容
临床试验/DRKS00016915
DRKS00016915已完成3 期

Fetal Atrial Flutter & Supraventricular Tachycardia (FAST) Therapy Trial - FAST

The Hospital for Sick Children0 个研究点目标入组 105 人开始时间: 2019年4月17日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
105

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
Female

入选标准

  • Mother has provided written informed consent to participate in the RCT
  • Mother aged =18 years at time of enrolment
  • Fetal AF without hydrops (RCT A) or SVT without hydrops (RCT B) or SVT with hydrops (RCT C)
  • Tachyarrhythmia that is significant enough to justify immediate transplacental pharmacological treatment:
  • - Tachycardia = 170 bpm during +100% of time (= 30 0/7 weeks of gestation)
  • - Tachycardia = 180 bpm during at least 10% of observation time
  • - Tachycardia = 280 bpm
  • - Tachycardia with fetal hydrops
  • Gestational age = 12 0/7 weeks and <36 0/7 weeks at time of enrolment
  • Untreated arrhythmia at time of enrolment
  • Singleton Pregnancy
  • Healthy mother with ± normal pre-treatment cardiovascular findings:
  • - ECG within normal range (sinus rhythm; QTc = 0.47; PR = 0.2 sec; QRS: = 0.12 sec; insignificant anomalies isolated premature beats; isolated complete right bundle branch block;non-specific ST-T segment changes allowed)
  • - Maternal resting heart rate = 50 bpm
  • - Maternal Systolic BP = 85 mm Hg

排除标准

  • Fetal AF with hydrops (condition is too infrequent to be studied in a separate RCT sub-study; eligible for Registry)
  • Any maternal-fetal conditions associated with high odds of premature delivery and/or death other than tachycardia (e.g. severe IUGR; premature rupture of membrane; life-threatening maternal disease (incl. pre-eclampsia; HELLP syndrome); severe congenital fetal abnormalities (T 13 or 18; surgery or death expected < 1 month))
  • History of significant maternal heart condition (open heart surgery; sick sinus syndrome; channelopathy (long QT, Brugada syndrome); ventricular tachycardia; WPW syndrome; high-degree heart block; cardiomyopathy)
  • History of significant maternal obstructive airway disease including asthma
  • Maternal serum potassium level < 3.3mmol/L / <3.3 mEq/L
  • Maternal ionized serum calcium level of <1 mmol/L / <4mg/dL or total serum calcium level <2mmol/L / < 8mg/dL
  • Maternal serum creatinine level > 97.2 µmol/L (>1.1 mg/dl)
  • Maternal intake of QT-prolonging medication including but not limited to the following medications: http://www.crediblemeds.org/pdftemp/pdf/CompositeList.pdf

研究者

相似试验